Innovative Research for the Future.

Innovating
for the Future

We are creating a better world through creative research for the future.
Quintrigen
R&D center

Quintrigen

p53 reactivation

YEDA, the technology holding company of Israel's Weizmann Institute of Science, has established Quintrigen, a local joint venture. This collaboration marks a significant step towards fostering technological innovation and advancement, focusing on cutting-edge research and technology commercialization


Restoring p53: The Key to Revolutionary Cancer Therapy

Damage to the p53 gene is found in over 50% of cancers. Restoring p53 could become an innovative cancer treatment.

Why p53 reactivation?

Tackling fundamental problems underlying cell proliferation and oncogenesis will provide an effective solution to develop an innovative, life-saving cancer therapy.
* Arrested cell proliferation
* Death of cancer cells
* Sensitiztion of refractory cancers

Restore p53's cancer suppression function using specific peptides.

- Screen promising peptide candidates using phage display libraries
- Synthesize peptides based on consensus motifs identified through bioinformatics
- Conduct ELISA-based semi-high throughput screening
- Lead peptide selection